SURVYR

GILD

Gilead Sciences, Inc.
$159.20
+$0.12 (0.08%)Oct 28 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-7%+4%+15%+26%+37%Oct 2025Oct 2026Apr 202652w high $160.5152w low $114.02
GILDSPY
Wall St. Highest PT $185.00 (+16.2%) Wall St. Avg PT $160.19 (+0.6%)
$115$134$153$172$191POC $123Hi $185Avg $160
Underwater Drawdown %Max DD -21.6%Current 0.0%
0.0%-21.6%
Relative Strength vs SPY+21.5% vs SPYOutperforming
+34%0%-34%
1W
+$5.63 (3.67%)
1M
+$6.99 (4.59%)
3M
+$27.21 (20.62%)
6M
+$31.92 (25.08%)
YTD
+$38.63 (32.04%)
1Y
+$44.16 (38.39%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
26 analysts · mean score 1.68
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$159.20
Average target$160.19
+$0.99 (+0.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$126.00
Median$160.19
High$185.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-20 · B of A Securities reiterated Buy on GILD
Reiterated
2026-10-08 · RBC Capital reiterated Sector Perform on GILD
Reiterated
2026-10-08 · Cantor Fitzgerald reiterated Overweight on GILD
Reiterated
2026-10-07 · Truist Securities reiterated Buy on GILD
Reiterated
2026-10-07 · JP Morgan reiterated Overweight on GILD
Reiterated
2026-10-07 · Morgan Stanley reiterated Overweight on GILD
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$193.5B
P/E (next 12 months, estimated)15.6
52-week range$114.02 – $160.51
Revenue growth (latest quarter vs a year ago)+10.2%
Dividend yield2.10%
Analyst consensusBuy (26)
Average analyst price target$160.19 (+1%)

What they do

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis.

Healthcare · Drug Manufacturers - General
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
61st percentile in sector
B-
12-1 return: +27.5%
Percentile within its GICS sector across the S&P 1500.
Growth
60th percentile in sector
B-
Revenue growth (YoY): +10.2%
Percentile within its GICS sector across the S&P 1500.
Value
59th percentile in sector
B-
Forward E/P: 6.4% · EBITDA/EV: 6.8%
Percentile within its GICS sector across the S&P 1500.
Profitability
10th percentile in sector
D-
Profit margin: -10.6% · Return on equity: -20.7%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 118 of 499 · 12-month momentum 34.3%
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 52 of 589 · 12-month momentum 32.4%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

GILD earningsReports today
Next report · quarter Sep 2026
Thu Oct 29, 2026After the close
EPS consensus$2.21 range $1.99–$2.68
Revenue consensus$7.8B 20 analysts
Last 4 quarters · EPS vs estimate
Aug 4, 2026-$6.75est -$7.25+6.9%Above estimates
May 7, 2026$2.03est $1.91+6.2%Above estimates
Feb 10, 2026$1.86est $1.81+2.8%Above estimates
Oct 30, 2025$2.47est $2.14+15.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-24 11:17:46 ET
24-1125-0225-0425-0825-1026-0226-0526-08-7.252.47
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$7.8B+10.2%
2026-03-31$7.0B–
2025-12-31$7.9B–
2025-09-30$7.8B–
2025-06-30$7.1B–

Recent dividends

2026-09-15: $0.820 · 2026-06-15: $0.820 · 2026-03-13: $0.820 · 2025-12-15: $0.790 · 2025-09-15: $0.790 · 2025-06-13: $0.790 · 2025-03-14: $0.790 · 2024-12-13: $0.770

News & catalysts

More news
Avantis U.S. Large Cap Value (AVLV) Sells $42.9 Million More MetLife on Friday
GuruFocus.com · Oct 27
ETFs Are Net Sellers of Gilead Sciences (GILD) on Oct. 23
GuruFocus.com · Oct 27
Gilead Sciences stock may move 4.6% on Oct. 29 earnings release
Investing.com · Oct 22
ETFs Are Net Sellers of Gilead Sciences (GILD) on Oct. 16
GuruFocus.com · Oct 20
ETF Activity: QQQ Outflows Offset SPY Inflows on Friday
GuruFocus.com · Oct 20
Rating changes
Reiterated
2026-10-20 · B of A Securities reiterated Buy on GILD
Reiterated
2026-10-08 · RBC Capital reiterated Sector Perform on GILD
Reiterated
2026-10-08 · Cantor Fitzgerald reiterated Overweight on GILD
Reiterated
2026-10-07 · Truist Securities reiterated Buy on GILD
Reiterated
2026-10-07 · JP Morgan reiterated Overweight on GILD
Reiterated
2026-10-07 · Morgan Stanley reiterated Overweight on GILD

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Mercier Johanna
Chief Comm & Corp Aff Officer · 2026-10-15
Sell
$468.7K
Dickinson Andrew D
Chief Financial Officer · 2026-10-15
Sell
$468.7K
O'Day Daniel Patrick
Director, Chairman & CEO · 2026-10-01
Sell
$445.9K
O'Day Daniel Patrick
Director, Chairman & CEO · 2026-10-01
Sell
$1.8M
Mercier Johanna
Chief Comm & Corp Aff Officer · 2026-09-15
Sell
$87.2K
Mercier Johanna
Chief Comm & Corp Aff Officer · 2026-09-15
Sell
$115.6K
Mercier Johanna
Chief Comm & Corp Aff Officer · 2026-09-15
Sell
$229.9K
Dickinson Andrew D
Chief Financial Officer · 2026-09-15
Sell
$435.9K
O'Day Daniel Patrick
Director, Chairman & CEO · 2026-09-01
Sell
$807.9K
O'Day Daniel Patrick
Director, Chairman & CEO · 2026-09-01
Sell
$1.2M
O'Day Daniel Patrick
Director, Chairman & CEO · 2026-09-01
Sell
$236.0K
Welters Anthony
Director · 2026-08-26
Sell
$1.0M

Stats refreshed 2026-10-24 11:17:46 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026